Trending News on Targeted Oncology, Week of September 11, 2020

September 11, 2020
Danielle Ternyila

Targeted Oncology reviews trending news online for the week of September 11, 2020, including recent news from the FDA, updates in oncology, and new information regarding COVID-19.

This week, the FDA granted an Orphan Drug designation to 2 agents, the first for the treatment of thymic epithelial tumors and the second for patients with chronic lymphocytic leukemia. A Breakthrough Therapy designation was also granted for the treatment of chemotherapy-induced neutropenia. A supplemental Biologics License Application has also been submitted to the FDA seeking approval of a treatment for patients with light chain amyloidosis.

Targeted Oncology brings you the latest coverage from the 8th annual meeting of the Society of Hematologic Oncology (SOHO).

These updates and others were trending this week:

Tweet Chat Recap: Evaluating Treatment Approaches for Relapsed/Refractory DLBCL

Kami J. Maddocks, MD, hosted a recent tweet chat discussion with Targeted Oncology, which evaluated the case of a 76-year-old man with relapsed/refractory diffuse large B-cell lymphoma. Maddocks recaps the treatment options discussed during this chat and shares her thoughts on the recent FDA approval of tafasitamab plus lenalidomide in this setting.

Expert Reviews Recent Approval and New Emerging Treatments in Follicular Lymphoma

In an interview with Targeted Oncology, Alan P. Z. Skarbnik, MD, discussed the current therapeutic strategies for treating patients with follicular lymphoma. He also highlights the recent advances in this space, including the recent approval of tazemetostat as treatment of patients with relapsed/refractory disease

Spira Analyzes the Use of Durvalumab in Unresectable Stage III NSCLC

Alex Spira, MD, PhD, discussed the use of durvalumab as treatment of a 63-year-old male with unresectable stage III non–small cell lung cancer.

FDA Informs on Lack of Efficacy and Safety of Atezolizumab/Paclitaxel in mTNBC

The combination of atezolizumab (Tecentriq) and paclitaxel was not effective for the treatment of patients with treatment-naïve inoperable locally advanced or metastatic triple-negative breast cancer, according to an FDA alert released to healthcare professionals and clinical trial investigators in oncology.

Nivolumab/Ipilimumab Established as New Standard in Frontline sRCC

The combination of nivolumab (Opdivo) plus ipilimumab (Yervoy) demonstrated long-term survival and response benefits as treatment of poor- to intermediate-risk patients with advanced renal cell carcinoma with sarcomatoid features (sRCC) compared with sunitinib (Sutent), according to published results from the phase 3 CheckMate 214 clinical trial.

Moving Beyond JAK Inhibitors in Myeloproliferative Neoplasms

Naveen Pemmaraju, MD, discusses the need to move beyond JAK inhibition when treating patients with myeloproliferative neoplasms.

Expert Perspectives Virtual Tumor Board: Clinical Cases in HER2+ Breast Cancer

Experts in breast oncology, including Ruta Rao, MD, Sara Tolaney, MD, MPH, Komal Jhaveri, MD, FACP, and Evita Sadimin, MD, review 3 clinical cases of HER2+ breast cancer and discuss individualized treatment approaches for each patient.